Welcome to our dedicated page for MEDIPHARM LABS news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on MEDIPHARM LABS stock.
MediPharm Labs Corp (MEDIF) is a pharmaceutical company specializing in precision-based cannabinoids. With GMP certification from ANVISA, FDA, EU, and TGA, MediPharm leads in pharmaceutical cannabinoids. They manufacture authorized medical cannabis products in compliance with strict regulations, including products for the Brazilian market under Resolution 327/19. By acquiring VIVO Cannabis, MediPharm expanded its reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.
MediPharm Labs (TSX: LABS, OTCQX: MEDIF) has entered into a share purchase agreement to sell its Napanee Facility to Kensana Health for $5.5 million in cash through the disposition of ABcann Medicinals. The transaction includes the facility's license, building, land, and equipment.
As part of the deal, both companies will form a strategic partnership through a supply and services agreement, utilizing MediPharm's GMP manufacturing capabilities. Kensana Health will supply select products to support MediPharm's international brands and customer base.
The transaction, expected to close by January 1, 2025, aligns with MediPharm's strategy to streamline operations and maximize stakeholder value. For Kensana Health, the acquisition supports its FDA registration process for a novel topical chronic wound treatment.
MediPharm Labs reported Q3 2024 financial results showing significant improvements. Net revenue reached $9.8M, a 15% increase from Q3 2023, with international medical cannabis revenue growing 37% and representing 36% of total revenue. Gross profit margin improved to 32%, up 29% from Q3 2023. The company completed its final $2.2M convertible debt payment, becoming debt-free with $13M cash balance. Adjusted EBITDA improved to negative $743K from negative $2.4M in Q3 2023. Notable growth was seen in German Beacon branded medical sales ($400K in Q3) and Australian wholesale sales ($2.5M in Q3).
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specializing in precision-based cannabinoids, announced it will release its third quarter financial results on November 14, 2024, before the market opens. The results will cover the three and nine months ended September 30, 2024.
An updated company presentation with select highlights from the period will be available on MediPharm's website following the release. Notably, the company will not host a quarterly earnings call.
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) has announced that President and Co-Founder Keith Strachan will step down from his management position effective December 31, 2024. Strachan will join the Board of Directors on January 1, 2025, continuing to provide strategic support and guidance. Since 2015, Strachan has been instrumental in shaping MediPharm Labs, co-founding the first extraction-only cannabis company and leading it to become the first commercial cannabis company in Canada to receive GMP site registration from the US FDA.
MediPharm Labs remains committed to providing high-quality, innovative cannabis solutions globally and ensuring the highest standards of production and compliance. The company will focus on growing internationally, maintaining its strong debt-free balance sheet, and enhancing profitability.
MediPharm Labs Corp. (MEDIF) reported improved financial results for Q2 2024. Net revenue increased 8% year-over-year to $10.3M, the highest in over three years. Gross profit margin improved significantly to 33% from 8.1% in Q2 2023. Adjusted EBITDA loss narrowed to $124K, a 96% improvement from Q2 2023. International revenue represented 44% of total revenue. The company made progress in pharma-quality cannabis innovation, doubling dronabinol sales and launching new products. Operating expenses were reduced by $2M compared to Q2 2023. MediPharm ended the quarter with a cash balance of $16 million and less than $3M in debt. Management expressed optimism about approaching profitability in the second half of 2024.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specialized in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. The company's executive management team will host a conference call and audio webcast on the same day at 8:30 a.m. Eastern time to discuss the financial results. Participants can join via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to attend the live event.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a pharmaceutical company specializing in precision-based cannabinoids, has announced the release date for its second quarter 2024 financial results. The results for the period ended June 30, 2024, will be released before markets open on Wednesday, August 14, 2024. Following the release, the company's executive management team will host a conference call and audio webcast at 8:30 a.m. (Eastern time) to discuss the financial results. Interested parties can join the call via a North America Toll-Free number or an International Toll number. An audio webcast will also be available, with a replay accessible on the company's website for those unable to participate live.
MediPharm Labs held its annual shareholder meeting on June 26, 2024, with 337 shareholders representing 14.72% of the company's issued shares. All resolutions were passed by a ballot vote.
The election of directors saw Michael Bumby, Chris Halyk, David Pidduck, Shelley Potts, and Chris Taves elected for the upcoming year. Voting results indicated strong support for Chris Halyk (93.15%) and David Pidduck (91.15%).
MNP LLP was appointed as the company's auditor until the next annual meeting, with 97.42% of votes in favor.
MediPharm Labs has secured global manufacturing, distribution, and sales rights for advanced medical cannabis delivery technologies from Remidose Aerosols. This includes metered dose inhalers and aerosol sublingual sprays. The transaction is non-dilutive and based on a performance-driven royalty model. Immediate revenue opportunities arise as MediPharm will take over Remidose's existing sales channels from August 2024, targeting Canadian direct-to-patient platforms and international distributors. MediPharm plans to utilize its GMP infrastructure to expand these products globally. The agreement aligns with MediPharm's strategy to innovate in non-smokable cannabis formats, enhancing its position in the pharmaceutical and wellness-focused sectors.
MediPharm Labs (TSX: LABS, OTCQB: MEDIF, FSE: MLZ) reported significant financial improvements for Q1 2024. Revenue rose by 67% to $9.8M compared to $5.8M in Q1 2023. Gross profit improved to $2.7M or 27% of revenue, up from 6.6% last year. Adjusted EBITDA loss decreased by 70% to $0.9M from $3.1M in Q1 2023. The company has $17M in cash and less than $3M in debt.
MediPharm is optimistic about potential US regulatory changes and plans to leverage its FDA and DEA credentials for future growth. Internationally, they saw a 36% increase in German medical cannabis sales to $1.4M and a 64% rise in Australian sales to $1.8M. CEO David Pidduck highlighted ongoing revenue growth, improved profitability metrics, and strong financial positioning for future investments.
FAQ
What is the current stock price of MEDIPHARM LABS (MEDIF)?
What is the market cap of MEDIPHARM LABS (MEDIF)?
What certifications does MediPharm Labs Corp hold?
What products does MediPharm Labs manufacture?
What was the significance of acquiring VIVO Cannabis?
When was MediPharm Labs Corp founded?
What is the core business of MediPharm Labs Corp?
What is the current financial position of MediPharm Labs Corp?
In which markets does MediPharm Labs operate?
What regulatory certifications did MediPharm Labs receive in 2021?
What is the significance of MediPharm Labs' GMP certification?
What is the expected growth of the Brazilian medical cannabis market?
